CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Z. Alexander Cao, Kathryn E. Bass, et al. Mol Cancer Ther 2006;5:1309-1317
The Histone Deacetylase Inhibitor PCI-24781 Induces Caspase and ROS-Dependent Apoptosis Through NF- B and is Synergistic with Bortezomib in Lymphoma Cells Savita Bhalla,Sriram Balasubramanian,et al. Clin Cancer Res 2009 May 15;15(10): 3354–3365
Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma Juehui Liu, Wenhong Ren, et al. Clin Cancer Res 2009;15:3472-3483
Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781 Judit P. Banáth, Susan H. MacPhail, et al. Clin Cancer Res 2007;13:6816-6826
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.